EMA consults on how to improve monitoring of clinical trials in third countries
This article was originally published in SRA
The European Medicines Agency has issued for public consultation a reflection paper that considers how to better monitor clinical trials that are conducted in third countries (ie outside the European Economic Area) and used to support marketing authorisation applications submitted to the agency1,2.
You may also be interested in...
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
The European Directorate for the Quality of Medicines & HealthCare is proceeding carefully to find the right balance between serving the diverse requirements of various stakeholders that make use of its ‘certificates of suitability.’
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.